Literature DB >> 31419926

Risk Factors, Mechanisms and Treatments of Thromboangiitis Obliterans: An Overview of Recent Research.

Meng-di Li1, Yi-Fan Wang2, Mei-Wen Yang3, Fen-Fang Hong4, Shu-Long Yang1.   

Abstract

BACKGROUND: Thromboangiitis obliterans (TAO) is a nonatherosclerotic thromboticocclusive vasculitis that affects the vessels of the small and medium-sized extremities. No explicit etiology or pathogenesis of TAO has been proven, and more effective treatments are needed.
OBJECTIVE: The study aimed to summarize and present an overview of recent advances regarding the risk factors, mechanisms and treatments of TAO and to organize the related information in figures to provide a comparatively complete reference.
METHODS: We searched PubMed for English-language literature about TAO without article type limits, including articles about the risk factors, pathological mechanisms and treatments of TAO in the last 10 years with essential supplements (references over ranges and English abstracts of Russian literature).
RESULTS: After screening content of works of literature, 99 references were evaluated. We found that risk factors of TAO include smoking, gene factors and periodontal diseases. The underlying mechanism of TAO involves oxidative stress, immunity, hemodynamic changes, inflammation and so on. Moreover, similarities in genetic factors and cigarette relevance existed between periodontal diseases and TAO, so further study of relationship was required. For TAO treatment, medicine, endovascular intervention and revascularization surgery, autologous cell therapy and novel therapies were also mentioned. Besides, a hypothesis that infection triggers autoimmunity in TAO could be speculated, in which TLR4 plays a key role.
CONCLUSION: 1. A hypothesis is put forward that infections can trigger autoimmunity in TAO development, in which TLR4, as a key agent, can activate immune signaling pathways and induce autoimmune cytokines expression. 2. It is suggested to reconsider the association between periodontal diseases and TAO, as they share the same high-risk population. Controlling periodontal disease severity in TAO studies may provide new clues. 3. For TAO treatment, endovascular intervention and autologous cell therapy both showed promising long-term therapeutic effectiveness, in which autologous cell therapy is becoming more popular, although more clinical comparisons are needed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Thromboangiitis obliterans; buerger’s disease; clinicalzzm321990features of TAO; pathological mechanism; risk-factors; treatments

Year:  2020        PMID: 31419926     DOI: 10.2174/0929867326666190816233042

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  4 in total

1.  The Imbalance among Oxidative Biomarkers and Antioxidant Defense Systems in Thromboangiitis Obliterans (Winiwarter-Buerger Disease).

Authors:  Hiva Sharebiani; Bahare Fazeli; Rosanna Maniscalco; Daniela Ligi; Ferdinando Mannello
Journal:  J Clin Med       Date:  2020-04-07       Impact factor: 4.241

2.  Integrated analysis of long non-coding RNA-microRNA-mRNA competing endogenous RNAregulatory networks in thromboangiitis obliterans.

Authors:  Bo Chen; Ying Deng; Bo Wang; Zhongyi Tian; Jindong Tong; Bo Yu; Weijun Shi; Jingdong Tang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  Autologous peripheral blood-derived stem cells transplantation for treatment of no-option angiitis-induced critical limb ischemia: 10-year management experience.

Authors:  Gang Fang; Xiaolang Jiang; Yuan Fang; Tianyue Pan; Hao Liu; Bichen Ren; Zheng Wei; Shiyang Gu; Bin Chen; Junhao Jiang; Yun Shi; Daqiao Guo; Peng Liu; Weiguo Fu; Zhihui Dong
Journal:  Stem Cell Res Ther       Date:  2020-10-28       Impact factor: 6.832

4.  Therapeutic Effect and Mechanism of Si-Miao-Yong-An-Tang on Thromboangiitis Obliterans Based on the Urine Metabolomics Approach.

Authors:  Hui-Yu Li; Hui Sun; Ai-Hua Zhang; Lu-Wen He; Shi Qiu; Jun-Ru Xue; Fangfang Wu; Xi-Jun Wang
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.